Pleural effusion VEGF levels as a prognostic factor of malignant pleural mesothelioma

Respiratory Medicine

Volumn 105, Issue 1, 2011, Pages 137-142

  Hirayama, Noriko ^a   Tabata, Chiharu ^a   Tabata, Rie ^b   Maeda, Risa ^a   Yasumitsu, Akihiro ^a   Yamada, Shusai ^a   Kuribayashi, Kozo ^a   Fukuoka, Kazuya ^a   Nakano, Takashi ^a  

^a HYOGO COLLEGE OF MEDICINE   (Japan)

^b Hyogo Prefectural Tsukaguchi Hospital   (Japan)

Author keywords

Cytokine; Mesothelioma; Tumor marker

Indexed keywords

PEMETREXED; VASCULOTROPIN;

ADVANCED CANCER; AGED; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE MARKER; FEMALE; HISTOPATHOLOGY; HUMAN; MALE; OVERALL SURVIVAL; PLEURA EFFUSION; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; THORACOCENTESIS;

AGED; AGED, 80 AND OVER; FEMALE; HUMANS; MALE; MESOTHELIOMA; PLEURAL EFFUSION; PLEURAL NEOPLASMS; PROGNOSIS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 78649955066     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rmed.2010.10.010     Document Type: Article

References (31)

1. B.W. Robinson, A.W. Musk, and R.A. Lake Malignant mesothelioma Lancet 366 2005 397 408
2. B.W. Robinson, and R.A. Lake Advances in malignant mesothelioma N Engl J Med 353 2005 1591 1603
3. J.C. Wagner, C.A. Sleggs, and P. Marchand Diffuse pleural mesothelioma and asbestos exposure in the North Western Cape province Br J Ind Med 17 1960 260 271
4. I.J. Selikoff, E.C. Hammond, and H. Seidman Latency of asbestos disease among insulation workers in the United States and Canada Cancer 15 1980 2736 2740
5. NJ Vogelzang, JJ Rusthoven, J Symanowski, MB Sporn, and AB Roberts Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma J Clin Oncol 21 2003 2636 2644
6. AK Nowak, RA Lake, HL Kindler, and BW Robinson New approaches for mesothelioma: biologics, vaccines, gene therapy, and other novel agents Semin Oncol 29 2002 82 96
7. C Fuhrman, JC Duche, C Chouaid, I Abd Alsamad, K Atassi, and I Monnet Use of tumor markers for differential diagnosis of mesothelioma and secondary pleural malignancies Clin Biochem 33 2000 405 410
8. M Paganuzzi, M Onetto, P Marroni, R Filiberti, E Tassara, and S Parodi Diagnostic value of CYFRA 21-1 tumor marker and CEA in pleural effusion due to mesothelioma Chest 119 2001 1138 1142
9. C Tabata, R Tabata, Y Kadokawa, S Hisamori, M Takahashi, and M Mishima Thalidomide prevents bleomycin-induced pulmonary fibrosis in mice J Immunol 179 2007 708 714
10. Yasumitsu A, Tabata C, Tabata R, et al. Clinical significance of serum VEGF in malignant pleural mesothelioma. J Thorac Oncol, in press.
11. L Strizzi, A Catalano, G Vianale, S Orecchia, A Casalini, and G Tassi Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma J Pathol 193 2001 468 475 (Pubitemid 32266815)
12. V.W. Rusch A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group Chest 108 1995 1122 1128
13. C Rake, C Gilham, J Hatch, A Darnton, J Hodgson, and J. Peto Occupational, domestic and environmental mesothelioma risks in the British population: a case-control study Br J Cancer 100 2009 1175 1183
14. HI Pass, D Lott, F Lonardo, M Harbut, Z Liu, and N Tang Asbestos exposure, pleural mesothelioma, and serum osteopontin levels N Engl J Med 353 2005 1564 1573
15. BW Robinson, J Creaney, R Lake, A Nowak, AW Musk, and N de Klerk Mesothelin-family proteins and diagnosis of mesothelioma Lancet 362 2003 1612 1616
16. T Frebourg, G Lerebours, B Delpech, D Bertrand, P Bertrand, and C Maingonnat Serum hyaluronate in malignant pleural mesothelioma Cancer 59 1987 2104 2107
17. H Schouwink, CM Korse, JM Bonfrer, A.A. Hart, and P Baas Prognostic value of the serum tumour markers cyfra 21-1 and tissue polypeptide antigen in malignant mesothelioma Lung Cancer 25 1999 25 32
18. J. Creaney, D. Yeoman, L.K. Naumoff, M. Hof, A. Segal, and A.W. Musk Soluble mesothelin in effusions: a useful tool for the diagnosis of malignant mesothelioma Thorax 62 2007 569 576 (Pubitemid 47056881)
19. C Tabata, R Tabata, N Hirayama, A Yasumitsu, S Yamada, and A Murakami All- trans-retinoic acid inhibits tumor growth of malignant pleural mesothelioma in mice Eur Respir J 34 2009 1159 1167
20. MA Versnel, L Claesson-Welsh, A Hammacher, MJ Bouts, TH van der Kwast, and A Eriksson Human malignant mesothelioma cell lines express PDGF beta-receptors whereas cultured normal mesothelial cells express predominantly PDGF alpha-receptors Oncogene 6 1991 2005 2011
21. DR Fitzpatrick, H Bielefeldt-Ohmann, RP Himbeck, AG Jarnicki, AL Marzo, and BW Robinson Transforming growth factor-beta: antisense RNA-mediated inhibition affects anchorage-independent growth, tumorigenicity and tumor-infiltrating T-cells in malignant mesothelioma Growth Factors 11 1994 29 44
22. AL Marzo, DR Fitzpatrick, BW Robinson, and B Scott Antisense oligonucleotides specific for transforming growth factor beta2 inhibit the growth of malignant mesothelioma both in vitro and in vivo Cancer Res 57 1997 3200 3207
23. IA Mórocz, D Schmitter, B Lauber, and RA Stahel Autocrine stimulation of a human lung mesothelioma cell line is mediated through the transforming growth factor alpha/epidermal growth factor receptor mitogenic pathway Br J Cancer 70 1994 850 856
24. G Galffy, KA Mohammed, PA Dowling, N Nasreen, MJ Ward, and VB Antony Interleukin 8: an autocrine growth factor for malignant mesothelioma Cancer Res 59 1999 367 371
25. JG Edwards, DE Swinson, JL Jones, S Muller, DA Waller, and KJ O'Byrne Tumor necrosis correlates with angiogenesis and is a predictor of poor prognosis in malignant mesothelioma Chest 124 2003 1916 1923
26. GD Yancopoulos, S Davis, NW Gale, JS Rudge, SJ Wiegand, and J. Holash Vascular-specific growth factors and blood vessel formation Nature 407 2000 242 248
27. R.K. Jain Molecular regulation of vessel maturation Nat Med 9 2003 685 693
28. N. Ferrara, H.P. Gerber, and J. LeCouter The biology of VEGF and its receptors Nat Med 9 2003 669 676
29. R Masood, A Kundra, S Zhu, G Xia, P Scalia, and DL Smith Malignant mesothelioma growth inhibition by agents that target the VEGF and VEGF-C autocrine loops Int J Cancer 104 2003 603 610
30. Q Li, S Yano, H Ogino, W Wang, H Uehara, and Y Nishioka The therapeutic efficacy of anti vascular endothelial growth factor antibody, bevacizumab, and pemetrexed against orthotopically implanted human pleural mesothelioma cells in severe combined immunodeficient mice Clin Cancer Res 13 2007 5918 5925
31. F Demirag, E Unsal, A Yilmaz, and A Caglar Prognostic significance of vascular endothelial growth factor, tumor necrosis, and mitotic activity index in malignant pleural mesothelioma Chest 128 2005 3382 3387